Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rogier W Sanders

Showing results (31-40 of 325) with videos related to

Pageof 33
Sort By:
Biochemical Society Transactions|May 23, 2018
Harnessing post-translational modifications for next-generation HIV immunogensJoel D Allen, Rogier W Sanders, Katie J Doores, et al.
AIDS Research and Human Retroviruses|April 19, 2011
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Per Johan Klasse, Rogier W Sanders, Andrea Cerutti, et al.
Cell Host & Microbe|April 10, 2020
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?P J Klasse, Gabriel Ozorowski, Rogier W Sanders, et al.
AIDS Research and Human Retroviruses|August 17, 2004
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structureRogier W Sanders, Els Busser, John P Moore, et al.
The Journal of Biological Chemistry|January 31, 2015
Immunosilencing a highly immunogenic protein trimerization domainKwinten Sliepen, Thijs van Montfort, Mark Melchers, et al.
AIDS Research and Human Retroviruses|June 19, 2015
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope GlycoproteinMarina R Alexander, Rogier W Sanders, John P Moore, et al.
Plos Pathogens|August 15, 2009
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryReem Berro, Rogier W Sanders, Min Lu, et al.
Journal of Virology|August 13, 2011
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionDirk Eggink, Ilja Bontjer, Johannes P M Langedijk, et al.
Virology|April 24, 2012
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistanceCleo G Anastassopoulou, Thomas J Ketas, Rogier W Sanders, et al.
Retrovirology|June 1, 2004
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41Rogier W Sanders, Martijn M Dankers, Els Busser, et al.
Pageof 33

Showing results (31-40 of 325) with videos related to

Sort By:
Pageof 33
Biochemical Society Transactions|May 23, 2018
Harnessing post-translational modifications for next-generation HIV immunogensJoel D Allen, Rogier W Sanders, Katie J Doores, et al.
AIDS Research and Human Retroviruses|April 19, 2011
How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Per Johan Klasse, Rogier W Sanders, Andrea Cerutti, et al.
Cell Host & Microbe|April 10, 2020
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?P J Klasse, Gabriel Ozorowski, Rogier W Sanders, et al.
AIDS Research and Human Retroviruses|August 17, 2004
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structureRogier W Sanders, Els Busser, John P Moore, et al.
The Journal of Biological Chemistry|January 31, 2015
Immunosilencing a highly immunogenic protein trimerization domainKwinten Sliepen, Thijs van Montfort, Mark Melchers, et al.
AIDS Research and Human Retroviruses|June 19, 2015
Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope GlycoproteinMarina R Alexander, Rogier W Sanders, John P Moore, et al.
Plos Pathogens|August 15, 2009
Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entryReem Berro, Rogier W Sanders, Min Lu, et al.
Journal of Virology|August 13, 2011
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionDirk Eggink, Ilja Bontjer, Johannes P M Langedijk, et al.
Virology|April 24, 2012
Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistanceCleo G Anastassopoulou, Thomas J Ketas, Rogier W Sanders, et al.
Retrovirology|June 1, 2004
Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41Rogier W Sanders, Martijn M Dankers, Els Busser, et al.
Pageof 33